Provenance Record

Well-structured, clinically accurate news article covering a significant FDA approval. The article correctly identifies the IMvigor011 trial (NCT04660344), reports accurate patient numbers (761 total, 250 ctDNA-positive, 167 atezolizumab, 83 placebo), and correctly states the May 15, 2026 approval date. All key efficacy numbers (DFS 9.9 vs 4.8 months, OS 32.8 vs 21.1 months, HRs 0.64 and 0.59) are verified against sources. Word count (835) is within the News category range.

All 5 sources verified from disk snapshots. source-0.html.gz (OncDaily, live): confirms approval date, trial design, patient counts, DFS/OS statistics, and ctDNA-negative 1-year/2-year DFS rates (95.4%/88.4%). source-1.html.gz (ONS, live): confirms May 15 approval, DFS HR=0.64 p=0.0047, OS HR=0.59 p=0.0131 with exact confidence intervals. source-2.html.gz (Oncozine, archive fallback from Dec 2025): confirms 36% DFS reduction, 41% OS reduction, grade 3/4 AE rates (28% vs 22%), fatal AE rates (3% vs 2%), and identifies 357 ctDNA-negative patients with 95% 1-year and 88% 2-year DFS. Levi Garraway quote source. source-3.html.gz (ASCO Post, live): confirms Bellmunt quote verbatim, 21.8-month follow-up for ctDNA-negative arm, Bellmunt's title as co-principal investigator and Director of Bladder Cancer Center at Dana-Farber. source-4.html.gz (CancerNetwork, live): confirms approval announcement, trial design, DFS and OS statistics. ONE ISSUE IDENTIFIED: The article quotes Levi Garraway as saying 'serial ctDNA testing to detect molecular residual disease may advance bladder cancer treatment.' Oncozine (the only source with this quote) reports the actual statement as: 'The use of serial ctDNA testing to detect molecular residual disease may also advance bladder cancer treatment by combining a precision diagnostic with cancer immunotherapy.' The article omits 'also' and truncates the second half of the sentence — a paraphrase inside quotation marks.

All trial statistics, patient numbers, hazard ratios, p-values, and CI ranges are accurately reported and verified against sources. The ctDNA-negative patient DFS rates (95.4% and 88.4%) match OncDaily. The 357 ctDNA-negative patient count is attributed to OncDaily in the article but appears explicitly only in Oncozine; OncDaily confirms the rates without naming the 357 count specifically. Both facts are substantiated in the cited sources. No fabricated specifics detected beyond the truncated Garraway quote.

Substantively strong, clinically accurate article on a landmark FDA approval. The single recoverable issue is a truncated Garraway quote presented inside quotation marks — a paraphrase, not a fabrication. All trial data, patient numbers, and survival statistics are accurately reported and verified. APPROVE_WITH_CORRECTIONS with a corrections record documenting the quote paraphrase.